By Sam Boughedda
Investing.com -- Biotechnology firm Novavax Inc (NASDAQ:NVAX) said Wednesday that it confirmed an immune response in both its stand-alone influenza vaccine and the Covid-19 combination vaccine.
The company added that there is a potential path forward for both.
Novavax stock initially spiked on the news but is now down 2%.
In a call with reporters, the company's Chief Medical Officer Filip Dubovsky reportedly said the early phase clinical trial uncovered that up to 25 micrograms of the Covid vaccine combined with up to 35 micrograms of the flu vaccine initiated a promising level of protective antibodies.
"The CIC [COVID-Influenza Combination Vaccine] trial demonstrated that formulating the combination vaccine is feasible, well-tolerated and immunogenic," Novavax said in its press release.
The company added that the data supports an advancement to a Phase 2 confirmation trial, which is expected to begin by the end of 2022.
Novavax doesn't yet have an authorized vaccine in the U.S., but earlier this week Japan's health ministry formally approved Novavax's Covid-19 shot.